Industry Focus

We compare Biogen's and Celgene's current valuations and consider what might be in store for Gilead Sciences now that its new hepatitis C drug is approved.

Direct download: 07062016_IF_Healthcare.mp3
Category:Podcast -- posted at: 12:12pm EST